Delgocitinib cream reduces itch and pain in adults with moderate to severe chronic hand eczema: pooled analyses of the phase 3 DELTA-1 and-2 trials

被引：0
|
作者：
Bauer, Andrea [1 ]
Schuttelaar, Marie-Louise [2 ]
Baranowski, Keith [3 ]
Plohberger, Ursula [3 ]
Sorensen, Laura [3 ]
Worm, Margitta [4 ]
机构：
[1] Tech Univ Dresden, Univ Allergy Ctr, Univ Hosp Carl Gustav Carus, Dept Dermatol, Dresden, Germany
[2] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands
[3] LEO Pharm A S, Ballerup, Denmark
[4] Charite Univ Med Berlin, Dept Dermatol Venerol & Allergy, Div Allergy & Immunol, Berlin, Germany
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷
关键词：
chronic hand eczema; delgocitinib; JAK;
D O I：
10.1093/bjd/ljae266.033
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
654
引用
收藏
页数：2
相关论文
共 49 条
  • [31] Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS
    Silverberg, Jonathan I.
    Yosipovitch, Gil
    Simpson, Eric L.
    Kim, Brian S.
    Wu, Jashin J.
    Eckert, Laurent
    Guillemin, Isabelle
    Chen, Zhen
    Ardeleanu, Marius
    Bansal, Ashish
    Kaur, Mandeep
    Rossi, Ana B.
    Graham, Neil M. H.
    Patel, Naimish
    Gadkari, Abhijit
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (06) : 1328 - 1336
  • [32] EVOLUTION OF EASI RESPONSE WITH LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO- SEVERE ATOPIC DERMATITIS: POOLED RESULTS FROM TWO PHASE 3 TRIALS (ADVOCATE1 AND ADVOCATE2) AT WEEK 16
    Wollenberg, Andreas
    Warren, Richard B.
    Silverberg, Jonathan I.
    Guttman-Yassky, Emma
    Thaci, Diamant
    Irvine, Alan D.
    Gold, Linda Stein
    Blauvelt, Andrew
    Simpson, Eric L.
    Chu, Chia-Yu
    Liu, Zhuqing T.
    Lima, Renata Gontijo
    Pillai, Sreekumar
    Gil, Esther Garcia
    Seneschal, Julien
    ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 53 - 53
  • [33] Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials
    Puig, L.
    Tsai, T. -F.
    Bhutani, T.
    Uy, J.
    Ramachandran, P.
    Song, M.
    You, Y.
    Gooderham, M.
    Lebwohl, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (08) : 1744 - 1749
  • [34] Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials
    Thaci, D.
    Jullien, D.
    Egeberg, A.
    Carrascosa, J. M.
    Wu, J. J.
    Pau-Charles, I.
    Gisondi, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (11) : E709 - E711
  • [35] Long-term safety of tildrakizumab in patients 65 years of age or older with moderate to severe psoriasis: Pooled analysis through 3 years (148 weeks) from reSURFACE 1 and reSURFACE 2 phase 3 trials
    van de Kerkhof, Peter C.
    Dauden, Esteban
    Pau-Charles, Ignasi
    Schoenenberger Lopez, Andreu
    Langley, Richard
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB120 - AB120
  • [36] ABROCITINIB TREATMENT IN ADOLESCENTS AND ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: EARLY PRURITUS RESPONSES FROM PHASE 3 TRIALS JADE MONO-1 AND JADE MONO-2
    Stander, Sonja
    Yosipovitch, Gil
    Silverberg, Jonathan I.
    Simpson, Eric L.
    Sinclair, Rodney
    Su, John C.
    Kerkmann, Urs
    Gallardo, William Romero
    Valdez, Hernan
    Rojo, Ricardo
    Biswas, Pinaki
    Farooqui, Saleem A.
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 56 - 56
  • [37] Dupilumab improves symptoms of anxiety and depression in adults with moderate-to-severe atopic dermatitis: A post hoc analysis of three phase 3 trials (LIBERTY AD SOLO 1 & 2 And CHRONOS)
    Silverberg, J.
    Thyssen, J. P.
    Armstrong, A.
    Gadkari, A.
    Chen, Z.
    Ardeleanu, M.
    Shumel, B.
    Rossi, A. B.
    Eckert, L.
    ALLERGY, 2019, 74 : 182 - 183
  • [38] Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks (vol 182, pg 605, 2020)
    Reich, K.
    Warren, R. B.
    Iversen, L.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (01) : 131 - 132
  • [39] ABROCITINIB TREATMENT IN ADOLESCENTS AND ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: KEY EFFICACY AND SAFETY RESULTS FROM PHASE 3 TRIALS JADE MONO-1 AND JADE MONO-2
    Simpson, Eric L.
    Silverberg, Jonathan I.
    Forman, Seth
    Wollenberg, Andreas
    Thyssen, Jacob P.
    Flohr, Carsten
    Feeney, Claire
    Biswas, Pinaki
    DiBonaventura, Marco
    Cameron, Michael C.
    Rojo, Ricardo
    Valdez, Hernan
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 13 - 14
  • [40] Dupilumab Improves Symptoms of Anxiety and Depression in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Three Phase 3 Trials (LIBERTY AD SOLO 1 & 2 and ADOL)
    Silverberg, Jonathan
    Soong, Weily
    Lockshin, Benjamin
    Gadkari, Abhijit
    Chen, Zhen
    Bansal, Ashish
    Eckert, Laurent
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB191 - AB191
12345